supported by the National Natural Science Foundation of the People's Republic of China(No.81070437,81270614 and 81300379);the National Science & Technology Pillar Program of China(No.2008BAI61B01)
For patients with chronic myeloid leukemia(CML) failing imatinib therapy,second-generation tyrosine kinase inhibitors(TKIs) are recommended.Here,we describe two patients with advanced CML who failed imatinib thera...